Due to the limitations of the present retrospective study (including from a single center, a small cohort, relatively short follow-up period and diversity of treatment), a multicenter prospective study would be required to further validate the potential value of serum CXCL5 as a biomarker for PC. Here, CXCL5 is linked to pachyonychia congenita.